Alaunos Therapeutics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $1.71
- 52-Week Range
- $0.72 – $4.50
- Market Cap
- $6.69M
- P/E (TTM)
- —
- EPS (TTM)
- -1.76
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 5.45
- PEG Ratio
- 0.58
- Return on Equity
- -192.00%
- Return on Assets
- -80.45%
- Gross Margin
- 0.00%
- Operating Margin
- -121033.34%
- Profit Margin
- 0.00%
- Current Ratio
- 1.14
- Debt/Equity
- —
- Total Debt
- $0.00
- Free Cash Flow
- $-1.13M
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $6.62M
Market Snapshot
About
Alaunos Therapeutics, Inc. is a clinical-stage cell therapy company focused on developing adoptive T cell receptor (TCR) therapies for the treatment of solid tumors. The company engineers patient T cells to recognize and attack cancer cells by targeting specific tumor-associated antigens. Alaunos is advancing multiple TCR programs for various cancer indications.